Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken-Ichi Harada

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Optics Letters|July 26, 2003
Dark-state imaging for two-dimensional mapping of a magnetic fieldHitoshi Asahi, Koji Motomura, Ken-ichi Harada, et al.
Urologic Oncology|November 19, 2013
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomyMasatomo Nishikawa, Hideaki Miyake, Ken-ichi Harada, et al.
Rapid Communications in Mass Spectrometry : RCM|February 24, 2007
Formation of diagnostic product ions from cyanobacterial cyclic peptides by the two-bond fission mechanism using ion trap liquid chromatography/multi-stage mass spectrometryTsuyoshi Mayumi, Hajime Kato, Yoshito Kawasaki, et al.
International Journal of Clinical Oncology|September 11, 2013
Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in JapanHideaki Miyake, Ken-Ichi Harada, Masafumi Kumano, et al.
Current Urology|June 12, 2014
Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladderKen-Ichi Harada, Hideaki Miyake, Tomoaki Terakawa, et al.
Urologic Oncology|January 29, 2014
Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomyHiromoto Tei, Hideaki Miyake, Ken-ichi Harada, et al.
Molecular Diagnosis & Therapy|May 15, 2016
Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinomaHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Medical Oncology (Northwood, London, England)|December 6, 2013
Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitorsMasatomo Nishikawa, Hideaki Miyake, Ken-Ichi Harada, et al.
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Optics Letters|July 26, 2003
Dark-state imaging for two-dimensional mapping of a magnetic fieldHitoshi Asahi, Koji Motomura, Ken-ichi Harada, et al.
Urologic Oncology|November 19, 2013
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomyMasatomo Nishikawa, Hideaki Miyake, Ken-ichi Harada, et al.
Rapid Communications in Mass Spectrometry : RCM|February 24, 2007
Formation of diagnostic product ions from cyanobacterial cyclic peptides by the two-bond fission mechanism using ion trap liquid chromatography/multi-stage mass spectrometryTsuyoshi Mayumi, Hajime Kato, Yoshito Kawasaki, et al.
International Journal of Clinical Oncology|September 11, 2013
Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in JapanHideaki Miyake, Ken-Ichi Harada, Masafumi Kumano, et al.
Current Urology|June 12, 2014
Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladderKen-Ichi Harada, Hideaki Miyake, Tomoaki Terakawa, et al.
Urologic Oncology|January 29, 2014
Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomyHiromoto Tei, Hideaki Miyake, Ken-ichi Harada, et al.
Molecular Diagnosis & Therapy|May 15, 2016
Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinomaHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Medical Oncology (Northwood, London, England)|December 6, 2013
Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitorsMasatomo Nishikawa, Hideaki Miyake, Ken-Ichi Harada, et al.
Pageof 15